Clinical Trials on Ovarian Endometrioma

Total 4893 results

Hospital Universitari de Bellvitge
Roche Diagnostic Ltd.

Completed

Antimullerian Hormone in Endometriomas

Endometriomas

Spain
Medical University of Vienna

Recruiting

Evaluating Ovarian Reserve After Conventional Laparoscopy Versus Robotic Surgery for Bilateral Endometrioma

Ovarian Endometrioma | Ovarian Endometriosis

Austria
Shanghai First Maternity and Infant Hospital
Shanghai Tongji Hospital, Tongji University School of Medicine; International...

Recruiting

Assessment of Ovarian Reserve After Laparoscopic Cystectomy Versus Aspiration/Electrocoagulation in the Treatment of Ovarian Endometrioma

Ovarian Reserve | Ovarian Endometrioma

China
Yonsei University

Recruiting

Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma

Ovarian Endometrioma

Korea, Republic of
Hospital Clinic of Barcelona

Completed

Randomized Study on Endometrioma Treatment

Ovarian Endometrioma

Spain
Yonsei University

Unknown

Vasopressin Injection Technique to Preserve Ovarian Reserve in Surgery for Unilateral Ovarian Endometriomas

Unilateral Ovarian Endometrioma

Korea, Republic of
Plasma Surgical Inc

Unknown

Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy

Ovarian Endometrioma

France
Cairo University

Unknown

Trans-vaginal Aspiration of Small Ovarian Endometrioma. Comparison of Two Different Techniques Before ICSI

Ovarian Endometrioma

Egypt
University of Cagliari
University of Foggia

Completed

Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Endometriomas

Ovarian Endometrioma

Italy
Shaimaa Mostafa Mohammed Refaay El shemy

Completed

Laparoscopic Ovarian Cystectomy Versus Aspiration and Coagulation in Ovarian Endometrioma

Ovarian Endometrioma

Egypt
Uludag University

Unknown

PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas

Ovarian Reserve, Endometrioma, PTEN-AKT-FOXO3 Gene Expression

Turkey
Far Eastern Memorial Hospital

Recruiting

The Association Between Ovarian Endometrioma and Lower Urinary Tract Symptoms

Ovarian Endometrioma

Taiwan
Uludag University

Unknown

Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial) (ERROR2)

Endometrioma | Ovarian Reserve

Turkey
Università degli Studi dell'Insubria

Not yet recruiting

Surgery and ART For Endometrioma

Infertility, Female | Ovarian Endometrioma
Mansoura University

Recruiting

Ultrasound Elastography in Diffferentiation of Endometriomas and Hemorrhagic Cysts

Ovarian Endometrioma

Egypt
Ain Shams University

Unknown

The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cysts.

Ovarian Endometrioma | Ovary Cyst

Egypt
Bagcilar Training and Research Hospital
Kocaeli Derince Education and Research Hospital; Suleymaniye Birth And Women...

Unknown

Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma

Ovarian Reserve

Turkey
Ankara University

Unknown

Association Between Laparoscopic Removal of Endometriomas and Anti-mullerian Hormone Levels

Endometriosis | Ovarian Reserve
Ankara University

Completed

Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas

Endometrioma | Ovarian Reserve

Turkey
McGill University Health Centre/Research Institute...

Not yet recruiting

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas (ERASE)

Endometrioma | Ovarian Endometrioma

Canada
University of Cagliari
University of Foggia; Azienda Ospedaliera per l'Emergenza Canizzaro

Completed

Evaluation of Ovarian Reserve and Recurrence Rate After DWLS Diode Laser OMA Vaporization (OMAlaser)

Endometrioma | Ovarian Endometrioma | Ovarian Endometriosis

Italy
National Cancer Institute (NCI)

Active, not recruiting

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Atypical Hyperplasia

United States
Piazza della Vittoria 14 Studio Medico - Ginecologia...

Recruiting

Ultrasonographic and Surgical Assessment of Endometriosis by AAGL 2021 Endometriosis Classification (ULTRA-AAGL)

Endometriosis | Deep Endometriosis | Ovarian Endometrioma | Bowel Endometriosis

Italy
HonorHealth Research Institute
Merck Sharp & Dohme LLC; Salarius Pharmaceuticals, LLC

Withdrawn

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Ovarian Endometrioid Adenocarcinoma | Endometrial Cancer | SCCOHT | Ovarian Clear Cell Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
Nuvectis Pharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Advanced Solid Tumor | Ovarian Clear Cell Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Clear Cell Tumor | Ovarian Endometrioid Tumor | ARID1A Gene Mutation

United States, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Fallopian Tube Carcinoma | Ovarian Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Ovarian...

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Recurrent Ovarian Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Uterine Corpus Cancer | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Germ Cell Tumor | Undifferentiated Ovarian Carcinoma | Ovarian Serous...

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian Undifferentiated...

United States
Women and Infants Hospital of Rhode Island

Unknown

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Grade 1 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Complex Atypical Endometrial Hyperplasia

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
Swiss GO Trial Group
Hoffmann-La Roche; Novartis Pharmaceuticals; AGO Study Group; Anticancer Fund,... and other collaborators

Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO)

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm Epithelial | High-grade Serous Ovarian Carcinoma (HGSOC) | Low-grade Serous Ovarian Carcinoma (LGSOC) | Ovarian Endometrioid Carcinoma

Austria, Switzerland, Germany
National Cancer Institute (NCI)

Completed

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Undifferentiated Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
Fudan University

Withdrawn

Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas

Endometrial Endometrioid Adenocarcinoma

China

Clinical Trials on Ovarian Endometrioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations